nilvadipine has been researched along with Heart Failure in 3 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The acute hemodynamic effects of nilvadipine, a newly synthesized calcium channel blocker, were studied in 12 patients with congestive heart failure." | 7.68 | Acute hemodynamic effects of nilvadipine, a new calcium channel blocker, in patients with congestive heart failure. ( Aoyagi, T; Iizuka, M; Ikenouchi, H; Matsui, H; Mochizuki, T; Momomura, S; Sato, H; Serizawa, T; Sugimoto, T, 1990) |
| " We conclude that the long-term administration of nilvadipine (16 mg daily) is neither effective nor harmful in the treatment of patients with chronic heart failure." | 6.67 | Long-term clinical effect of nilvadipine in patients with chronic heart failure: a double-blind placebo-controlled study. ( Hayashi, T; Hoki, N; Hori, M; Kamada, T; Karita, M; Kodama, K; Naka, M; Nanto, S; Sato, H; Yamada, Y, 1994) |
| "The acute hemodynamic effects of nilvadipine, a newly synthesized calcium channel blocker, were studied in 12 patients with congestive heart failure." | 3.68 | Acute hemodynamic effects of nilvadipine, a new calcium channel blocker, in patients with congestive heart failure. ( Aoyagi, T; Iizuka, M; Ikenouchi, H; Matsui, H; Mochizuki, T; Momomura, S; Sato, H; Serizawa, T; Sugimoto, T, 1990) |
| " We conclude that the long-term administration of nilvadipine (16 mg daily) is neither effective nor harmful in the treatment of patients with chronic heart failure." | 2.67 | Long-term clinical effect of nilvadipine in patients with chronic heart failure: a double-blind placebo-controlled study. ( Hayashi, T; Hoki, N; Hori, M; Kamada, T; Karita, M; Kodama, K; Naka, M; Nanto, S; Sato, H; Yamada, Y, 1994) |
| "Nilvadipine is a new calcium antagonist of the dihydropyridine type." | 2.38 | Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist. ( Honerjäger, P; Seibel, K, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hori, M | 1 |
| Sato, H | 2 |
| Karita, M | 1 |
| Kodama, K | 1 |
| Hoki, N | 1 |
| Hayashi, T | 1 |
| Naka, M | 1 |
| Nanto, S | 1 |
| Yamada, Y | 1 |
| Kamada, T | 1 |
| Honerjäger, P | 1 |
| Seibel, K | 1 |
| Ikenouchi, H | 1 |
| Aoyagi, T | 1 |
| Matsui, H | 1 |
| Mochizuki, T | 1 |
| Momomura, S | 1 |
| Serizawa, T | 1 |
| Iizuka, M | 1 |
| Sugimoto, T | 1 |
1 review available for nilvadipine and Heart Failure
| Article | Year |
|---|---|
Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Channels; Heart; | 1992 |
1 trial available for nilvadipine and Heart Failure
| Article | Year |
|---|---|
Long-term clinical effect of nilvadipine in patients with chronic heart failure: a double-blind placebo-controlled study.
Topics: Calcium Channel Blockers; Double-Blind Method; Exercise Tolerance; Female; Heart Failure; Hemodynami | 1994 |
1 other study available for nilvadipine and Heart Failure
| Article | Year |
|---|---|
Acute hemodynamic effects of nilvadipine, a new calcium channel blocker, in patients with congestive heart failure.
Topics: Aged; Aged, 80 and over; Blood Pressure; Calcium Channel Blockers; Female; Heart Failure; Hemodynami | 1990 |